AstraZeneca analysing 'inconsistent' results from Bevespi Aerosphere trial
(Sharecast News) - AstraZeneca announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) on Thursday.
